Katharine Dunlop
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Katharine Dunlop has a total of 514 co-authors. Here are the top co-authors by number of shared publications:
- Jonathan Downar
Department of Psychiatry and Institute of Medical Science, Faculty of Medicine, University of Toronto, Toronto
6 shared publications Sidney H. Kennedy
Centre for Depression and Suicide Studies, St. Michael's Hospital, Unity Health Toronto, Toronto, ON, Canada; Institute of Medical Science, Temerty Faculty of Medicine, University of Toronto, 6 Queen's Park Crescent, Toronto, ON M5S 3H2, Canada; Department of Psychiatry, Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
5 shared publicationsDaniel M. Blumberger
Departments of Psychiatry, Pharmacology & Toxicology, and Institute of Medical Science, University of Toronto, Canada
4 shared publications- Conor Liston
Weill Cornell Medicine
3 shared publications - Faith M. Gunning
Department of Psychiatry, Weill Cornell Medicine, New York, New York
3 shared publications Roumen Milev
Department of Psychiatry, Queen's University, Providence Care, Kingston, Ontario, Canada
3 shared publications
Latest Publications
- Open Access
- 25 July 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (5) , 103173
Proximity to an SGC–DLPFC individualized functional target and electric-field modeling do not predict clinical outcomes of rTMS for treatment-resistant depression
- 25 July 2026
- Published by Elsevier in Brain Stimulation
- Vol. 19 (5) , 103173
Open AccessProximity to an SGC–DLPFC individualized functional target and electric-field modeling do not predict clinical outcomes of rTMS for treatment-resistant depression
- Open Access
- 14 June 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152728
Neuroimaging insights on sleep disturbances and risk for major depressive disorder in youth: A systematic review
- 14 June 2026
- Published by Elsevier in Comprehensive Psychiatry
- Vol. 149, 152728
Open AccessNeuroimaging insights on sleep disturbances and risk for major depressive disorder in youth: A systematic review
- Open Access
Assessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
Open AccessAssessing the clinical effects of accelerated iTBS across the spectrum of treatment-resistant depression: Clinical outcomes of the PRISM-UTRD trial
Importance: Conventional repetitive transcranial magnetic stimulation (rTMS) can be ineffective in individuals who have previously failed brain stimulation, ketamine and/or multiple lines of therapies. Modern accelerated rTMS protocols using image-guided targets have not been systematically investigated in these individuals. The goal of this study was to assess the feasibility and efficacy of personalized, connectivity-guided, accelerated intermittent theta-burst stimulation (iTBS) in patients with treatment-resistant depression (TRD) of varying refractoriness. Objective: To assess whether connectivity-guided, accelerated iTBS produces significant reductions in depression severity, and to what extent this benefit extends to ultra treatment-resistant depression (UTRD). Design: This was an open-label feasibility trial of connectivity-guided, accelerated iTBS in patients with TRD. Two distinct groups of participants were recruited from a neurosurgical-psychiatry clinic with UTRD and an interventional psychiatry clinic with TRD. Patients were stratified into a priori treatment-resistance subgroups. Patients received five days of open-label treatment. Outcome measures were collected immediately prior to and after treatment, as well as at 4- and 12-weeks post-treatment. Setting: This trial ( NCT05813093 ) was conducted between November 2023 and July 2025 at Sunnybrook Health Sciences Centre in Toronto, Ontario, Canada. Participants: Patients with major depressive disorder. A total of 96 participants were screened, with 73 meeting eligibility criteria (UTRD=30, TRD=43). One withdrew due to inability to tolerate the baseline MRI, and the other withdrew voluntarily prior to treatment. Intervention: Participants underwent a neuronavigated accelerated iTBS (600 pulses) protocol using personalized left dorsolateral prefrontal cortex (dlPFC) targets derived from functional magnetic resonance imaging (fMRI), comprising eight daily treatments, repeated over five days. Main Outcomes: Primary outcomes were i) change in Hamilton Depression Rating Scale (HAM-D17) from baseline to the end of the fifth day of treatment, and ii) the difference in change in HAM-D17 between UTRD and TRD subgroups. Results: Connectivity-guided fMRI targeting yielded personalized targets clustered around the anterolateral dlPFC. Accelerated iTBS elicited rapid antidepressant effects (ΔHAM-D17 -9.01 [SD 6.06], t = -12.45, p < 0.001) regardless of treatment-resistance group (ΔHAM-D17 -9.64 [SD 5.94] vs -8.10 [SD 6.12], t = -1.05, p = 0.299), which were sustained up to 12 weeks after treatment. Overall response and remission rates at the end of treatment were 40.8% and 16.9%. Self-report scales revealed broad symptomatic relief outside of core depressive symptoms. Conclusions & Relevance: This study demonstrated that fMRI connectivity-guided, accelerated iTBS induces sustained antidepressant effects and broader psychiatric benefits in patients across the spectrum of TRD. In a cohort unlikely to respond to most antidepressant therapies, connectivity-guided, accelerated iTBS offers a safe, well-tolerated option that can achieve benefit, or when ineffective, allow patients to expeditiously proceed with subsequent therapies than conventional rTMS. Trial Registration: This clinical trial was registered at clinicaltrials.gov with NCT05813093 .
- Open Access
- 31 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 225
Subgenual anterior cingulate cortex in major depression: a systematic review and meta-analysis of MRI studies with patients and healthy controls
Background This systematic review aims to synthesize anatomical and functional magnetic resonance imaging (MRI) findings in the subgenual anterior cingulate cortex (sgACC) and associated network among medication-free patients with major depressive disorder (MDD) compared to healthy controls. Methods A search for published studies was performed through Ovid (MEDLINE, Embase, APA PsycINFO) on 18 April 2024. The JBI Critical Appraisal Tools and a modified version of the specialist protocol for MRI research were used for the quality assessment. Random-effects and activation likelihood estimation (ALE) meta-analyses were applied to studies reporting numerical and stereotactic data, respectively. Results Forty-two publications were reviewed. There was an equal split between the number of studies (n = 5) reporting reduced sgACC GM volume vs. no difference in MDD, with both findings supported by significant ALE clusters with peaks in the right sgACC (p ≤ .0005). Four task-based activity studies reported overactive sgACC in MDD, whereas 6 reported no difference. Both findings were supported by two significant ALE clusters with peaks in the right sgACC (p ≤ .00001). Eleven studies highlighted the global reduced resting-state network coherence of the sgACC in MDD, and reduced coherence with ventromedial prefrontal cortex (p = .00004) and right insula (p = .00002) was replicated across several reports. Conclusions Results highlight laterality and voxel-wise differences across subregions of the sgACC, displaying non-uniform GM volume, activity, and network coherence patterns in MDD. High-resolution parcellation of the sgACC should be considered in future MRI investigations.
- 31 March 2026
- Published by Springer Nature in Translational Psychiatry
- Vol. 16 (1) , 225
Open AccessSubgenual anterior cingulate cortex in major depression: a systematic review and meta-analysis of MRI studies with patients and healthy controls
Background This systematic review aims to synthesize anatomical and functional magnetic resonance imaging (MRI) findings in the subgenual anterior cingulate cortex (sgACC) and associated network among medication-free patients with major depressive disorder (MDD) compared to healthy controls. Methods A search for published studies was performed through Ovid (MEDLINE, Embase, APA PsycINFO) on 18 April 2024. The JBI Critical Appraisal Tools and a modified version of the specialist protocol for MRI research were used for the quality assessment. Random-effects and activation likelihood estimation (ALE) meta-analyses were applied to studies reporting numerical and stereotactic data, respectively. Results Forty-two publications were reviewed. There was an equal split between the number of studies (n = 5) reporting reduced sgACC GM volume vs. no difference in MDD, with both findings supported by significant ALE clusters with peaks in the right sgACC (p ≤ .0005). Four task-based activity studies reported overactive sgACC in MDD, whereas 6 reported no difference. Both findings were supported by two significant ALE clusters with peaks in the right sgACC (p ≤ .00001). Eleven studies highlighted the global reduced resting-state network coherence of the sgACC in MDD, and reduced coherence with ventromedial prefrontal cortex (p = .00004) and right insula (p = .00002) was replicated across several reports. Conclusions Results highlight laterality and voxel-wise differences across subregions of the sgACC, displaying non-uniform GM volume, activity, and network coherence patterns in MDD. High-resolution parcellation of the sgACC should be considered in future MRI investigations.
- Open Access
- 31 October 2025
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 6 (2) , 100649
Socioeconomic Status Is Associated With Reward Processing, Interleukin 1β, Striatal Connectivity, and Antidepressant Outcomes in Individuals With Major Depressive Disorder: A CAN-BIND-1 Report
- 31 October 2025
- Published by Elsevier in Biological Psychiatry Global Open Science
- Vol. 6 (2) , 100649
Open AccessSocioeconomic Status Is Associated With Reward Processing, Interleukin 1β, Striatal Connectivity, and Antidepressant Outcomes in Individuals With Major Depressive Disorder: A CAN-BIND-1 Report
- 12 March 2025
- Published by Elsevier in Biological Psychiatry
- Vol. 97 (7) , 661-663
When, How, and Where: Combining Psychotherapy and Neuromodulation for Obsessive-Compulsive Disorder
- 12 March 2025
- Published by Elsevier in Biological Psychiatry
- Vol. 97 (7) , 661-663
When, How, and Where: Combining Psychotherapy and Neuromodulation for Obsessive-Compulsive Disorder
- 1 July 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (1) , 230-245
Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression
Treatment outcomes widely vary for individuals diagnosed with major depressive disorder, implicating a need for deeper understanding of the biological mechanisms conferring a greater likelihood of response to a particular treatment. Our improved understanding of intrinsic brain networks underlying depression psychopathology via magnetic resonance imaging and other neuroimaging modalities has helped reveal novel and potentially clinically meaningful biological markers of response. And while we have made considerable progress in identifying such biomarkers over the last decade, particularly with larger, multisite trials, there are significant methodological and practical obstacles that need to be overcome to translate these markers into the clinic. The aim of this review is to review current literature on brain network structural and functional biomarkers of treatment response or selection in depression, with a specific focus on recent large, multisite trials reporting predictive accuracy of candidate biomarkers. Regarding pharmaco- and psychotherapy, we discuss candidate biomarkers, reporting that while we have identified candidate biomarkers of response to a single intervention, we need more trials that distinguish biomarkers between first-line treatments. Further, we discuss the ways prognostic neuroimaging may help to improve treatment outcomes to neuromodulation-based therapies, such as transcranial magnetic stimulation and deep brain stimulation. Lastly, we highlight obstacles and technical developments that may help to address the knowledge gaps in this area of research. Ultimately, integrating neuroimaging-derived biomarkers into clinical practice holds promise for enhancing treatment outcomes and advancing precision psychiatry strategies for depression management. By elucidating the neural predictors of treatment response and selection, we can move towards more individualized and effective depression interventions, ultimately improving patient outcomes and quality of life.
- 1 July 2024
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 50 (1) , 230-245
Breakthroughs and challenges for generating brain network-based biomarkers of treatment response in depression
Treatment outcomes widely vary for individuals diagnosed with major depressive disorder, implicating a need for deeper understanding of the biological mechanisms conferring a greater likelihood of response to a particular treatment. Our improved understanding of intrinsic brain networks underlying depression psychopathology via magnetic resonance imaging and other neuroimaging modalities has helped reveal novel and potentially clinically meaningful biological markers of response. And while we have made considerable progress in identifying such biomarkers over the last decade, particularly with larger, multisite trials, there are significant methodological and practical obstacles that need to be overcome to translate these markers into the clinic. The aim of this review is to review current literature on brain network structural and functional biomarkers of treatment response or selection in depression, with a specific focus on recent large, multisite trials reporting predictive accuracy of candidate biomarkers. Regarding pharmaco- and psychotherapy, we discuss candidate biomarkers, reporting that while we have identified candidate biomarkers of response to a single intervention, we need more trials that distinguish biomarkers between first-line treatments. Further, we discuss the ways prognostic neuroimaging may help to improve treatment outcomes to neuromodulation-based therapies, such as transcranial magnetic stimulation and deep brain stimulation. Lastly, we highlight obstacles and technical developments that may help to address the knowledge gaps in this area of research. Ultimately, integrating neuroimaging-derived biomarkers into clinical practice holds promise for enhancing treatment outcomes and advancing precision psychiatry strategies for depression management. By elucidating the neural predictors of treatment response and selection, we can move towards more individualized and effective depression interventions, ultimately improving patient outcomes and quality of life.
- 26 April 2024
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 9 (8) , 786-799
Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder
- 26 April 2024
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 9 (8) , 786-799
Atypical Brain Aging and Its Association With Working Memory Performance in Major Depressive Disorder
- 5 April 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (4) , 347-348
Establishing the Clinical Potential of Brain Aging in Depression: Implications for Suicidality and Antidepressant Response
- 5 April 2023
- Published by Elsevier in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging
- Vol. 8 (4) , 347-348
Establishing the Clinical Potential of Brain Aging in Depression: Implications for Suicidality and Antidepressant Response